IDEAYA: Positive Darovasertib Data In Neo-Adjuvant Melanoma Sets Next Catalyst (IDYA)

IDEAYA Biosciences is well-capitalized, with a cash runway into 2029 and multiple upcoming catalysts. Click here to find out why IDYA is upgraded to Strong Buy.